Niramai vs Predible Health

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Niramai employs 50-200 people, while Predible Health has 10-50 employees.

Niramai has raised more in total funding at $17M, compared to Predible Health's $5M — a gap of $12M.

Niramai holds the higher Awaira Score at 60/100, compared to Predible Health's 50/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

Niramai was founded by Geetha Manjunath in 2016. Predible Health was founded by Sanjoy Paul in 2017. Visit each company's profile on Awaira for a full founder biography.

Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare innovation and a major Indian public health challenge. Predible Health: Predible Health develops AI software for radiology and medical imaging analysis, with a focus on automated CT scan interpretation for lung nodule detection, COVID-19 assessment, and liver segmentation. The platform integrates with radiology information systems and PACS to provide AI-assisted second reads and quantitative measurements that reduce reporting time and flag critical findings for urgent review.\n\nThe company raised approximately $5M in Series A funding and has established clinical partnerships with hospital networks and diagnostic imaging centers across India. Predible Health received significant validation through its COVID-19 CT analysis tool, which was deployed during the pandemic to help overwhelmed radiology departments manage surge volumes.\n\nRadiology AI represents one of the most commercially mature segments of medical AI globally, with clear clinical workflows, measurable radiologist productivity benefits, and established reimbursement pathways emerging in developed markets. Predible Health's India-focused deployments position it as a domestic alternative to global radiology AI companies, with the advantage of deep integration knowledge in Indian hospital IT environments.

Niramai was founded first in 2016, giving it 1 year of additional market experience. Predible Health was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Niramai has approximately 50-200 employees, while Predible Health has approximately 10-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Niramai and Predible Health are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.